Dec 2022: I-Atezolizumab (Tecentriq, Genentech, Inc.) igunyazwe yi-Food and Drug Administration (FDA) yeziguli zabantu abadala kanye nezingane ezinengxenye ethambile ye-alveolar engabonakali noma ene-metastatic esineminyaka engu-2 ubudala.